Bnp Paribas Asset Management Holding S.A. Biocryst Pharmaceuticals Inc Transaction History

Bnp Paribas Asset Management Holding S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$6.71 - $7.92 $129,113 - $152,396	-19,242 Reduced 0.8%	2,390,948 $16.9 Million
Q2 2023 Aug 08, 2023	SELL	$6.96 - $8.81 $3.32 Million - $4.21 Million	-477,549 Reduced 16.54%	2,410,190 $17 Million
Q1 2023 May 08, 2023	BUY	$7.94 - $11.84 $201,294 - $300,167	25,352 Added 0.89%	2,887,739 $24.1 Million
Q4 2022 Feb 09, 2023	BUY	$10.5 - $14.2 $6.11 Million - $8.26 Million	581,434 Added 25.49%	2,862,387 $32.9 Million
Q3 2022 Nov 10, 2022	BUY	$10.79 - $14.81 $1.96 Million - $2.69 Million	181,626 Added 8.65%	2,280,953 $28.7 Million
Q2 2022 Aug 04, 2022	BUY	$7.89 - $17.88 $3.42 Million - $7.76 Million	434,071 Added 26.07%	2,099,327 $22.2 Million
Q1 2022 May 12, 2022	SELL	$11.56 - $19.76 $2.61 Million - $4.46 Million	-225,904 Reduced 11.95%	1,665,256 $27.1 Million
Q4 2021 Feb 09, 2022	BUY	$11.18 - $15.46 $21.1 Million - $29.2 Million	1,891,160 New	1,891,160 $26.2 Million

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Bnp Paribas Asset Management Holding S.A., based on Form 13F filings with the SEC.

Stay updated on Bnp Paribas Asset Management Holding S.A. with notifications on news.